In a nutshell This phase 3 clinical trial will test the effectiveness of acalabrutinib (ACP-196) with rituximab (Rituxan) and bendamustine (Treanda) in treating patients with previously untreated mantle cell lymphoma. The primary outcome will be measured by the time until the disease progresses. The details Acalabrutinib is an investigational...
Read MoreNon-Hodgkin lymphoma Posts on Medivizor
Looking for patients to test the safety of CAR T-cells in treating relapsed or refractory non-Hodgkin’s lymphoma
In a nutshell This phase 1 clinical trial will test the safety of JCAR017 CAR T-cells in treating patients with relapsed or refractory (unresponsive to treatment) B-cell non-Hodgkin’s lymphoma. The primary outcome with be measured by adverse (negative) side effects, maximum dosage, response rate, and concentration of JCAR017. The...
Read MoreLooking for patients with relapsed or refractory follicular or diffuse large B-cell lymphoma to test a combination therapy containing polatuzumab vedotin antibody-drug conjugate
In a nutshell This phase 2 clinical trial will test the safety and effectiveness of polatuzumab vedotin with obinutuzumab (Gazyva) and venetoclax (Venclexta) in patients with relapsed or refractory follicular lymphoma (FL) or rituximab (Rituxan) with polatuzumab vedotin and venetoclax in patients with relapsed or refractory diffuse large B-cell...
Read MoreLooking for patients with diffuse large B-cell lymphoma or stage 3b follicular lymphoma to test an antibody-drug conjugate with chemotherapy
In a nutshell This phase 2 clinical trial will determine the effectiveness of denintuzumab mafodotin (SGN-CD19A) with RICE chemotherapy in patients with relapsed or refractory (unresponsive to treatment) diffuse large B-cell lymphoma (DLBCL) or stage 3b follicular lymphoma (FL). The primary outcome will be measured by the complete remission...
Read MoreRisk factors for the development of new cancers in patients with follicular lymphoma
In a nutshell This study looked at risk factors for the development of new cancers in patients who have follicular lymphoma. The authors concluded that being over 65 years old, being male, and receiving radiation therapy are the greatest risk factors for the development of a new cancer. Some background Follicular lymphoma (FL) is a common type of...
Read MoreEvaluation and treatment of “double hit” lymphoma
In a nutshell The author describes his treatment approach to “double hit” lymphoma. The author concludes that patients with “double hit” lymphoma should be treated aggressively with high intensity treatment. Some background A new category of diffuse large b-cell lymphoma (DLBCL) was classified in 2016. This type of...
Read MoreFDA News Releases and Signing Up for Alerts
You may not know this but you can get warnings from the FDA on problems with prescription medications and over-the-counter drugs. For example, on August 11, a FDA News Release issued this warning about over-the-counter liquid vitamins that are given to young children and those who cannot swallow pills. “The U.S. Food and Drug Administration is...
Read MoreOccurrence of new cancers after rituximab treatment for patients with diffuse large B-cell lymphoma
In a nutshell The authors examined whether rituximab was associated with the development of a second cancer after treatment for diffuse large B-cell lymphoma. The authors concluded that the number of patients with certain cancers has increased after rituximab was introduced. Some background Diffuse large B-cell lymphoma (DLBCL) is a very...
Read MoreThe use of rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma
In a nutshell The authors looked at the effect of rituximab (Rituxan) treatment after autologous stem cell transplantation in patients with mantle cell lymphoma. The authors concluded that the use of rituximab after autologous stem cell transplantation improves outcomes for patients with mantle cell lymphoma. Some background Mantle cell...
Read MoreLong term outcomes for patients with advanced follicular lymphoma treated with FCM chemotherapy
In a nutshell The authors looked at the long-term outcomes for patients with advanced follicular lymphoma when treated with fludaranine, cyclophosphamide, and mitoxantrone (FCM). The authors concluded that FCM leads to long-lasting response with low rates of negative effects. Some background Follicular lymphoma (FL) is effectively treated with...
Read MoreInfluence of weight on survival for patients with indolent and mantle cell non-Hodgkin lymphoma
In a nutshell This study examines the effect of body mass index (BMI, a measure of body fat that takes height and weight into account) on the survival of patients with indolent and mantle cell lymphomas. The authors concluded that BMI affects the overall survival of patients with indolent and mantle cell lymphoma. Some background Obesity is...
Read MoreAllogenic stem cell transplantation in non-Hodgkin lymphoma
In a nutshell The authors looked at the outcomes for patients with non-Hodgkin lymphoma (NHL) who have undergone allogeneic stem cell transplantation. The study concluded that even patients with aggressive NHL should consider allogeneic stem cell transplantation. Some background There are mutliple subtypes of non-Hodgkin lymphoma (NHL). Some...
Read More
